GLUTHEALTH: Gluten Sensibility in Elite Athletes

Sponsor
University Hospital, Clermont-Ferrand (Other)
Overall Status
Completed
CT.gov ID
NCT03101410
Collaborator
Centre de Recherche en Nutrition Humaine d'Auvergne (Other), Institut National de la Recherche Agronomique (Other), Institut Carnot Qualiment (Other)
51
1
2
11.6
4.4

Study Details

Study Description

Brief Summary

This clinical project aims to study the relationship between gluten consumption and its impact on digestive comfort, quality of life and performance of non-celiac athletes practicing an intensive physical activity..

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Gluten
  • Behavioral: Gluten free
N/A

Detailed Description

Gluten is a protein network that results from both, the hydration and the kneading of storage proteins contained in the endosperm of certain cereals. Gluten is particularly found in bread products but it is also found in many processed products because of its physicochemical properties (binding, swelling properties ...). This omnipresence is now blamed, and a growing percentage of the population reports "intolerance" to gluten. This gluten sensitivity hypothesis is frequently associated with intestinal disorders (irritable bowel syndrome, bloating, abdominal pain, chronic diarrhea, constipation) but also with headache, fatigue, muscle and joint aches, bone fragility, migraine, eczema, depression, anxiety .... This assumption has led to the adoption of increasingly frequent gluten-free diets among the general population, without medical justification.

Among the population, athletes are particularly concerned due to a higher prevalence of anaphylaxis dependent on the combination of physical exercise and food intake (Maulitz and Kidd syndrome). This syndrome is notably reported with consumption of cereals in particular wheat (bread, pasta). However, these conditions are poorly described with regards to gluten and scientific investigations are required to rationally characterize the benefits of gluten-free diets for elite athletes.

Therefore, this clinical project aims to study the relationship between gluten consumption and its impact on digestive comfort, quality of life and performance of non-celiac athletes practicing an intensive physical activity.

All the participants will give freely their written informed consent before their selection in the study.

Information on physical activities, demographics, anthropometrics, vital signs, relevant medical history and concomitant medication, dietary habits, usual dietary intake and nutritional supplements will be collected. All inclusion and exclusion criteria will be checked by the investigator or co-investigator.

Selected participants will be randomly allocated to treatment group (gluten or gluten free). Couple from the same family will be randomised in the same group.

After 2 months, all subjects will have the diet without gluten.

All recruited volunteers will be asked to replace their bread and pasta intake by study products (pasta and white bread with or without gluten), maintain their usual dietary habits and continue their normal physical habits.

Each 2 months, volunteers will have a physical performance assessment and will provide a blood and faeces samples. All volunteers will complete a follow-up questionnaire to obtain information about any changes in medication use, disease etc. Each week, all subjects will complete a questionnaire related to digestive function :Food Benefits Assessment (FBA)).

At the beginning and 2 months, usual dietary intakes will be estimated by means of a 3- days food records.

Study Design

Study Type:
Interventional
Actual Enrollment :
51 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Participant)
Masking Description:
single blind
Primary Purpose:
Prevention
Official Title:
Gluten Sensibility in Elite Athletes
Actual Study Start Date :
Apr 1, 2017
Actual Primary Completion Date :
Mar 21, 2018
Actual Study Completion Date :
Mar 21, 2018

Arms and Interventions

Arm Intervention/Treatment
Experimental: gluten

Selected participants will be randomly allocated to treatment group (gluten or gluten free)

Behavioral: Gluten
Selected participants will be randomly allocated to treatment group (gluten or gluten free).

Experimental: gluten fee

Selected participants will be randomly allocated to treatment group (gluten or gluten free)

Behavioral: Gluten free
Selected participants will be randomly allocated to treatment group (gluten or gluten free).

Outcome Measures

Primary Outcome Measures

  1. Food Benefits Assessment (FBA) [at the beginning of the study, at 2 month and 4 month]

Secondary Outcome Measures

  1. Physicals performances assessment : 3000m running performance [at the beginning of the study, at 2 month and 4 month]

  2. Microbiota composition analysis on faeces samples [at the beginning of the study, at 2 month and 4 month]

    Microbiote composition will be measured by qPCR, targeting 16S gene

  3. Changes in body composition measured by bioelectrical impedance [at the beginning of the study, at 2 month and 4 month]

  4. Qualities life index for digestive disorders modified (GIQLI assessment modified) [at the beginning of the study, at 2 month and 4 month]

  5. Inflammatory cytokines [at the beginning of the study, at 2 month and 4 month]

  6. Bone and joint cytokines [at the beginning of the study, at 2 month and 4 month]

  7. Immune function from lymphocytes [at the beginning of the study, at 2 month and 4 month]

    Their reactivity will be studied in the presence of three different forms of gliadins: native, deaminated and hydrolysed

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Male and female trained >7h/week or more of 5 training/week

  • Member of a sports federation or medical certificate fewer 3 months

  • VO2 max estimated >125% of the theoretical value

  • Regular consumption of gluten under different products

  • Healthy (apparently free of diseases) and without any medical treatment

  • Without digestive diseases and non-coeliac disease

  • Affiliated to National Health Insurance

  • Having normal capacity of training to enter in the study procedures

  • Having provided her written informed consent

Exclusion Criteria:
  • Medicals or surgical histories, evaluated non compatible by the investigator

  • Diseases known

  • Antibiotherapy 2 months before the study

  • Gluten-free diet

  • Individual unable to give informed consent or refusing to sign informed consent

  • Being in exclusion on the National Volunteers Data file or refusing to be registered on the National Volunteers Data file

  • Currently participating or who having got 4500€ in this year before to have participating in another clinical trial

Contacts and Locations

Locations

Site City State Country Postal Code
1 CHU Clermont-Ferrand Clermont-Ferrand France 63003

Sponsors and Collaborators

  • University Hospital, Clermont-Ferrand
  • Centre de Recherche en Nutrition Humaine d'Auvergne
  • Institut National de la Recherche Agronomique
  • Institut Carnot Qualiment

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University Hospital, Clermont-Ferrand
ClinicalTrials.gov Identifier:
NCT03101410
Other Study ID Numbers:
  • CHU-308
  • 2016-A00356-45
First Posted:
Apr 5, 2017
Last Update Posted:
Jun 11, 2018
Last Verified:
Jun 1, 2018
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by University Hospital, Clermont-Ferrand
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 11, 2018